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Abstract
With the growing incidence of HIV, there is a desperate need to develop simple, cheap and effective new ways of preventing
HIV infection. Male circumcisionreduces the risk of infectionby about 60%, probably because of the removal of the Langerhans
cells which are abundant in the inner foreskin and are the primary route by which HIV enters the penis. Langerhans cells form a
vital partof the body’s naturaldefence against HIV and only causeinfection when they are exposed tohighlevelsof HIV virions.
Rather than removing thisnatural defencemechanism bycircumcision, it may bebetter toenhance itby thickening the layer of
keratin overlying the Langerhans cells, thereby reducing the viral load to which they are exposed. We have investigated the
ability of topically administered oestrogen to induce keratinization of the epithelium of the inner foreskin. Histochemically, the
whole of the foreskin is richly supplied with oestrogen receptors. The epithelium of the inner foreskin, like the vagina, responds
within 24 hours to the topical administration of oestriol by keratinization, and the response persists for at least 5 days after the
cessation of the treatment. Oestriol, a cheap, readily available natural oestrogen metabolite, rapidly keratinizes the inner
foreskin, the site of HIV entry into the penis. This thickening of the overlying protective layer of keratin should reduce the
exposure of the underlying Langerhans cells to HIV virions. This simple treatment could become an adjunct or alternative to
surgical circumcision for reducing the incidence of HIV infection in men.
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Introduction
In 2006, 39.5 million people were currently infected with HIV,
and there were 4.3 million new infections, making HIV one of the
greatest health crises in human history. There is a desperate need
to develop new methods to prevent HIV infection. The results of
three large randomised trials of male circumcision, carried out in
South Africa [1], Kenya [2] and Uganda [3], leave no doubt that
circumcision more than halves a man’s risk of HIV infection [4,5],
and the protective effect is thought to be due to the physical
removal of most of the inner foreskin epithelium. This epithelium
is richly supplied with Langerhans cells, the main site of HIV entry
into the penis [6]. However, Langerhans cells are also a vital part
of the body’s natural epithelial defence against HIV infection,
since they contain the c-type lectin Langerin that normally
degrades any virions entering the cell [7,8]. When large amounts
of virus are present, the Langerin reserves may be depleted, so that
the Langerhans cells instead become vectors for transporting virus
to the regional lymph nodes, establishing a systemic infection.
Langerhans cells are also the primary site of HIV entry into the
female reproductive tract [9]. It has long been known that the
human vaginal epithelium responds to topical oestrogen admin-
istration by thickening and keratinization, and vaginal oestrogen
cream or tablets are widely used by postmenopausal women to
treat vaginal atrophy [10,11]. The vaginal epithelial structure has
a direct effect on its susceptibility to HIV infection. A decline in
oestrogen levels in women after the menopause is associated with a
four to eightfold increased risk of contracting HIV [12].
To determine how oestrogen affects the susceptibility of the
vaginalepitheliumtoHIVinfection,ovariectomisedRhesusmonkeys
were treated with either intravaginal oestriol or base cream and then
challengedintravaginallywithSimianImmunodeficiencyVirus(SIV)
[13]. Oestriol treated animals showed a dramatically increased
resistance to SIV infection; only one of the twelve oestriol treated
animals became infected when challenged with SIV, compared to six
of the eight ovariectomised controls (p=0?0044) [13]. The treated
animals did become infected if the SIV was injected beneath the
vaginal epithelium, showing that the resistance to infection was
occurringattheepithelialsurface.Theincreased keratinizationofthe
vaginal epithelium induced by the topical oestriol treatment
apparently helped to reduce the number of SIV virions from coming
into contact with the Langerhans cells, thus preventing infection.
The inner foreskin is a mucosal epithelium similar to that of the
postmenopausal vagina, with a very thin layer of overlying keratin
giving little protection to the underling Langerhans cells [6]. We
have examined the ability of topical oestrogen to increase keratin
production by the inner foreskin epithelium. By thickening the
overlying protective layer of keratin, it may be possible to reduce
the viral load to which the Langerhans cells are exposed, thus
increasing resistance to HIV infection.
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Inorderto determineiftheinnerforeskincould respond totopical
oestriol, we examined the mRNA expression and protein distribu-
tion of the two oestrogen receptors (ER) ERa and ERb,i nt h e
foreskins of six adult men aged 30–65, undergoing elective surgical
circumcisions. mRNA transcripts for both ERa and ERb were
detected in samples taken from the inner and outer foreskin (Figure
S1). ERa and ERb protein was detected immunohistochemically at
high levels in the epidermis of both the inner and outer foreskinof all
six men (Figure 1). ERa waspredominantly located inthe epidermis.
Staining was strongest in the stratum granulosum cells and in the
stratum basale with weakest staining in the stratum spinosum. ERb
staining was slightly more intense but similar in distribution to ERa.
ERb was more prevalent in the dermis than ERa. These results
showed that the epithelial cells of the inner foreskin should be able to
respond to topical oestrogen administration.
We then examined the ability of oestriol cream to induce
keratinization of the inner foreskin of men in vivo. Topical
oestrogen (Ovestin: Organon, 0.5 ml of cream containing 500
micrograms of oestriol) was applied daily to the inner foreskin of
two men. The number of desquamated cornified epithelial cells
was recorded in daily contact smears of the inner foreskin (Figure 2,
S2) to assess the level of keratinisation. The treatment produced a
highly significant increase in the number of desquamated,
keratinised epithelial cells within 24 hours of the first oestriol
application and this effect persisted for at least five days after the
cessation of treatment (Figure 2).
Discussion
The localisation of both ERa and ERb in the inner foreskin
epithelium, and the increase in keratinization following topical
oestrogen treatment, are consistent with the well-documented local
effects of oestrogen in the female reproductive tract [9,10]. Our
findings demonstrate that topical oestrogen can induce rapid
keratinisation of the inner foreskin. Further studies are now
needed to determine if this can protect the Langerhans cells from
contact with HIV virions.
In order to avoid any adverse systemic side effects of the topically
applied oestrogen, it will be important to determine the minimal
effective dose and frequency of application needed to produce the
keratinization response. We have chosen to use oestriol since it is a
weak, naturally occurring oestrogen metabolite that is normally
present in human male urine, and it is unlikely to cause
hypothalamic inhibition or gynecomastia. Similar treatment regi-
mens in women [14] had no effecton circulating LH concentrations.
A similar keratinisation response was detected in the vaginal
epithelium of Rhesus monkeys using as little as 25 mg of oestriol
applied twice weekly [13]. Topical oestriol doses as low as these
would only induce a local response and would probably be
insufficient to cause any changes in circulating oestriol concentra-
tions and systemic side effects.
If the increase in keratinisation of the inner foreskin can prevent
HIV entry into the penis, there will be many potential uses for this
treatment. Surgical circumcisiononlyconfersa 60%protective effect
Figure 1. ERa (a) and ERb (b) protein distribution (brown
staining) in the inner and outer aspects of the foreskin. ERa
staining was strongest in the stratum granulosum cells (black
arrowheads) and in the stratum basale (red arrowheads) with weakest
staining in the stratum spinosum. Natural variation in the thickness of
the keratin layer is evident between samples (black bars). ERb shows a
similar localisation, but was more prevalent in the dermis than ERa.
Negative controls were incubated without primary antibody and with
an equivalent amount of non-specific rabbit IgG; as expected there was
no staining observed. Melanocytes are present in some sections as
histologically dark cells found at the base of the epidermis (yellow
arrowheads) and do not indicate staining. Enlarged panels show
characteristic cytoplasmic, nuclear and peri-nuclear staining for ERa and
ERb in the epithelium.
doi:10.1371/journal.pone.0002308.g001
Figure 2. Quantification of desquamated keratin from contact
smears. The mean amount of desquamated keratin was calculated for
each individual for each treatment period. A highly significant increase
in keratin was observed between the 4-day pre-treatment (Pre) and the
14-day treatment periods (Standard T-test; p=0?002 individual 1 and
p=0?00003 individual 2 indicated by *). A significant increase in keratin
was maintained over the 5-day post treatment period (Post) (p=0?02
for individual 1 and p=0?01 for individual 2 as indicated by **).
doi:10.1371/journal.pone.0002308.g002
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inner foreskin. Perhaps topical oestrogen administration might be
able to keratinise the residual inner foreskin tissue, increasing the
overall protective effect of circumcision. There is also a significantly
increased risk of contracting HIV after circumcision if sexual activity
is resumed before sufficient wound healing has occurred [15].
Topicaloestrogen hasbeen shown to hastenwound healing[16] and
could also be used before and after circumcision to reduce the
postoperative wound healing time. Furthermore, whilst male
circumcision is undoubtedly effective [17,18], implementing it is a
daunting task, particularly in countries like India, China and most of
South-East Asia where it is culturally unacceptable [15]. In such
cases, topical oestrogen could provide a medical alternative to
circumcision to reduce HIV infection. Oestrogen cream could even
be used as a condom lubricant that might ultimately protect the man
and the woman.
Thus, this simple, cheap, readily available natural hormone
could create a living barrier to HIV that preserves the natural
defences of the inner foreskin. The oestrogen treatment could be
an invaluable adjunct or alternative to surgical circumcision for
reducing the incidence of HIV infection in men.
Materials and Methods
RT-PCR
Inner and outer aspects of the foreskin were separated and total
RNA was extracted from each separately using the GenElute
Total RNA extraction mini kit (Sigma). Extracted RNA was then
treated with DNase (DNAfree - Ambion) at 37uC for 30 minutes.
RNA was reverse transcribed using a dT primer and the
Superscript Reverse Transcription Kit (Invitrogen). PCR primers
were designed to span introns; ERa forward 59 ACTGCATCA-
GATCCAAGGGAACG 39 and reverse 59 GGCAGCTCT-
CATGTCTCCAGCAGA 39 amplify an 825-bp ERa fragment
and ERb forward 59 AGCAGCTGCACTGTGCCGGCAAG 39
and reverse 59 CCTCTGCCGGGCTGCACTCGGA 39 amplify
an 839-bp ERb fragment [19].
Immunohistochemistry
Tissue sections (8 mm) were treated with 3% hydrogen peroxide
in methanol for 15 minutes to quench endogenous peroxidase
activity. Antigen retrieval was performed in a microwave on
defrost for 20 minutes in 0?5M Sodium citrate pH6?0. Slides were
blocked in 10% normal goat serum in phosphate buffered saline.
Sections were incubated with primary antibody (NeoMarkers ER
Ab-16 and ER-beta Ab-24) at a 1:400 dilution at 4uC overnight.
Antibody binding was detected with goat anti-rabbit biotinylated
secondary antibody (Santa Cruz) and amplified using the ABC kit
(Vector Labs). Antibody localisation was visualised using 3-amino-
9-ethylcarbazole chromogen (red/brown staining, AEC - Vector
Labs). Negative controls were incubated with an equivalent
amount of non-specific rabbit IgG to primary antibody. Tissues
were counterstained with haematoxylin.
Topical Oestrogen treatment
Two sexually inactive uncircumcised males (74 and 33 years of
age) applied 500 mg of oestriol in 0.5 ml of base cream (Ovestin;
Organon; 1 mg oestriol/ml) to the preputial sac daily for 14 days.
Contact smears were collected daily for four days preceding the
treatment, during the treatment, and for six days post-treatment.
Assessment of Keratinisation response
Contact smears were taken once daily, immediately before
application of the oestrogen cream. The foreskin was retracted to
expose its inner surface. A poly-L lysine coated glass slide was
briefly placed in contact with the exposed inner foreskin surface.
Slides were fixed in 70% ethanol, air dried and stored at room
temperature until batch staining at the end of the trial. Slides were
stained using the Ayoub-Shklar [20] method for visualisation of
keratin (shown as brilliant red staining).
Supporting Information
Figure S1 ERa (top panel) and ERb (bottom panel) RT-PCR. 1,
negative control with template omitted. 2, MCF7 cDNA template
(used as a positive control for amplification). 3, inner foreskin
sample #1. 4, outer foreskin sample #1. 5, inner foreskin sample
#2. 6, outer foreskin sample #2. ERa amplification was
performed on all samples; ERb was performed on sample #2
only. Clear amplification was observed for both receptors in both
inner and outer foreskin.
Found at: doi:10.1371/journal.pone.0002308.s001 (0.86 MB TIF)
Figure S2 Randomly selected representative images of the
stained contact smears in the pre-treatment, treatment and post
treatment periods for the two individuals. Keratin stains bright
pink. The amount of desquamated keratin increased markedly
within 24 hours of beginning the treatment and remained
significantly higher than the control period for up to 5 days after
cessation of the treatment. Quantification of the desquamated
epithelial cells is shown in Figure 2.
Found at: doi:10.1371/journal.pone.0002308.s002 (3.80 MB TIF)
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